Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 4/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 7/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 7/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.38 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5423924 | 0.90 | TAS1R3 (0.42) | PYGLCYP2C9ALDH1A1HSD17B10TAS1R3 | |
| SCHEMBL5411481 | 0.89 | PYGL (0.49) | PYGLCYP2C9ALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL5424475 | 0.86 | TAS1R3 (0.50) | PYGLCYP2C9TAS1R3TAS1R1KDR | |
| SCHEMBL5424479 | 0.86 | TAS1R3 (0.50) | PYGLCYP2C9TAS1R3TAS1R1KDR | |
| SCHEMBL5194508 | 0.85 | LNPEP (0.48) | PYGLCYP2C9TAS1R3TAS1R1KDR | |
| SCHEMBL5218743 | 0.84 | TAS1R3 (0.48) | PYGLCYP2C9TAS1R3TAS1R1KDR | |
| SCHEMBL5195321 | 0.83 | PYGL (0.52) | PYGLCYP2C9ALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL5420020 | 0.82 | PYGL (0.49) | PYGLCYP2C9ALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL5417140 | 0.81 | PYGL (0.50) | PYGLCYP2C9ALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL5420846 | 0.79 | TAS1R3 (0.62) | TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1812383-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Smithkline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | PYGL 2/4885CYP2C9 2982/4885ALDH1A1 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.